Biologic Pharmamedical CEO Franco Cavaleri tells Proactive the group, together with Naturally Splendid Enterprises Ltd (CVE:NSP) (OTCQB:NSPDF) has received a Notice of Authorization from Health Canada to proceed with a Phase 2 clinical trial for a potential COVID-19 treatment utilizing the target drug Cavaltinib. Cavaleri says within 60-90 days the company should be able to begin the trial. Cavaleri says he hopes Cavaltinib will show positive results in mitigating the 'cytokine storm' with COVID-19 patients
Naturally Splendid Enterprises greenlit to begin Phase 2 study for its potential COVID-19 treatment
Quick facts: Naturally Splendid Enterprises Ltd.
Price: 0.045 CAD
Market Cap: $9.81 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...FOR OUR FULL DISCLAIMER CLICK HERE